Patents by Inventor Sachio Okuda
Sachio Okuda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9623075Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.Type: GrantFiled: May 28, 2013Date of Patent: April 18, 2017Assignee: THE CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTEInventors: Shinji Nakahira, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
-
Patent number: 9278133Abstract: A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.Type: GrantFiled: October 26, 2007Date of Patent: March 8, 2016Assignees: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, TOKUSHIMA UNIVERSITYInventors: Tetsuhiro Harakawa, Hirotoshi Nakano, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Sachio Okuda, Ryuji Kaji, Shunji Kosaki
-
Patent number: 8949033Abstract: The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin.Type: GrantFiled: April 28, 2006Date of Patent: February 3, 2015Assignees: The Chemo-Sero-Therapeutic Research Institute, Japan as represented by Director General of National Institute of Infectious DiseasesInventors: Tetsuhiro Harakawa, Hirotoshi Nakano, Yasushi Torii, Sachio Okuda, Ryuji Kaji, Takashi Sakamoto, Motohide Takahashi, Setsuji Ishida
-
Patent number: 8577618Abstract: The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin.Type: GrantFiled: April 28, 2006Date of Patent: November 5, 2013Assignees: The Chemo-Sero-Therapeutic Research Institute, Japan as represented by Director Genereal of National Institute of Infectious DiseasesInventors: Tetsuhiro Harakawa, Hirotoshi Nakano, Yasushi Torii, Sachio Okuda, Ryuji Kaji, Takashi Sakamoto, Motohide Takahashi, Setsuji Ishida
-
Patent number: 8569238Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: GrantFiled: March 18, 2013Date of Patent: October 29, 2013Assignees: The Chemo-Sero-Therapeutic Research Institute, Ginkyo Academy Kumamoto Health Science University, National University Corporation Kumamoto UniversityInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
-
Publication number: 20130252902Abstract: A method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin. The method includes administering 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX) to the patient. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation containing a type A1 botulinum toxin.Type: ApplicationFiled: May 28, 2013Publication date: September 26, 2013Applicant: THE CHEMO-SERO THERAPEUTIC RESEARCH INSTITUTEInventors: Shinji NAKAHIRA, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
-
Publication number: 20130224179Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: ApplicationFiled: March 18, 2013Publication date: August 29, 2013Inventors: SHINTARO KAMEI, ASAMI SHINDOME, TAKAYOSHI HAMAMOTO, HIROAKI MAEDA, MASAKI HIRASHIMA, SACHIO OKUDA, MISAKO UMEHASHI, SACHIE OGAWA, MEGUMI IMUTA, NORIO AKAIKE, KAZUO TAKAHAMA, RYOKO WADA
-
Publication number: 20120225818Abstract: The activated Factor XI is provided as an antitussive for cough caused by the stimulation at the tracheal bifurcation such as chronic cough. A pharmaceutical composition for prevention, treatment and/or symptom amelioration of cough, comprising a polypeptide chain as an active ingredient and a pharmaceutically acceptable carrier, wherein the polypeptide chain consists of a full length amino acid sequence constituting activated Factor XI (hereinafter also referred to as “FXIa”), the amino acid sequence with one or several amino acids therein being deleted, substituted or added, or a partial sequence of either of the above amino acid sequences, or an amino acid sequence comprising as a part any of the above amino acid sequences.Type: ApplicationFiled: August 5, 2010Publication date: September 6, 2012Applicants: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE, NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY, GINKYO ACADEMY KUMAMOTO HEALTH SCIENCE UNIVERSITYInventors: Shintaro Kamei, Asami Shindome, Takayoshi Hamamoto, Hiroaki Maeda, Masaki Hirashima, Sachio Okuda, Misako Umehashi, Sachie Ogawa, Megumi Imuta, Norio Akaike, Kazuo Takahama, Ryoko Wada
-
Publication number: 20110033431Abstract: A pharmaceutical preparation for use in a patient who has a neutralizing antibody to a botulinum toxin from type A1 Clostridium botulinum (type A1 botulinum toxin), said preparation comprising as an active ingredient 150 kDa type A neurotoxin from type A2 Clostridium botulinum (A2 NTX); a medicament for treating a disease with muscle overactivity for use in a patient who has a neutralizing antibody to a type A1 botulinum toxin, said medicament comprising as an active ingredient said A2 NTX; a method for treating a patient who has a neutralizing antibody to a type A1 botulinum toxin, said method comprising administering said A2 NTX to the patient; and a method for use of A2 NTX in a patient who has said neutralizing antibody. In accordance with the present invention, a problem can be solved of decrease in clinical response caused by a neutralizing antibody to a type A1 botulinum toxin produced when a patient is treated with a pharmaceutical preparation comprising a type A1 botulinum toxin.Type: ApplicationFiled: March 31, 2009Publication date: February 10, 2011Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTEInventors: Shinji Nakahira, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Satomi Munechika, Sachio Okuda, Shunji Kozaki
-
Publication number: 20100173841Abstract: A novel type A botulinum toxin preparation is provided. A neuromuscular transmission blocking agent comprising as an active ingredient a highly purified type A botulinum toxin from Clostridium botulinum as infant botulism pathogen and a medicament for treating a disease with a muscle overactivity comprising as an active ingredient said toxin. In particular, the medicament of the present invention, as compared to the conventional known botulinum toxin preparations, has rapid efficacy of potential and is less diffusive and thus, having a broader safety margin, may be used as therapeutic medicament for decreasing local, muscle overactivity in a disease with a muscle overactivity.Type: ApplicationFiled: October 26, 2007Publication date: July 8, 2010Applicant: Juridical Foundation the Chemo-Sero-Therapeutic Research InstituteInventors: Tetsuhiro Harakawa, Hirotoshi Nakano, Yasushi Torii, Yoshitaka Goto, Miho Shinmura, Sachio Okuda, Ryuji Kaji, Shunji Kosaki
-
Publication number: 20090297452Abstract: The present invention relates to a method for quantitatively measuring the muscular relaxing activity of a neurotoxin.Type: ApplicationFiled: April 28, 2006Publication date: December 3, 2009Inventors: Tetsuhiro Harakawa, Hirotoshi Nakano, Yasushi Torii, Sachio Okuda, Ryuji Kaji, Takashi Sakamoto, Matohide Takahashi, Setsuji Ishida